The early days of genomics were marked by concerns that wide-ranging gene patents would restrict research and medical discovery. So far, proteomics hasn't toiled under the same cloud. But don't get complacent, warns David Cyranoski.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cyranoski, D. This protein belongs to.... Nature 426, 10–11 (2003). https://doi.org/10.1038/426010a
Issue date:
DOI: https://doi.org/10.1038/426010a
This article is cited by
-
Intellectual property and the commercialization of research and development
Science and Engineering Ethics (2005)
